|Slideshows|December 9, 2016

Year in Review: 2016 CMEs

Here is a year's worth of CMEs you can take right now.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

ByLeah Kuntz

June 4th 2026

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

ByKim Do, PhD,Jessica Walters

June 3rd 2026

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

ByWilliam Li, MD,Morgan Hardy, MD

June 2nd 2026

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Year in Review: 2016 CMEs

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Suicide Risk Assessment in Patients Denying Suicidal Intent

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis